Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

This is a real-world registry study following Chinese children with Crohn's disease (a chronic inflammatory bowel condition) who are receiving infliximab (a biologic medication) for the first time. The goal is to collect data on how well the drug works and whether it is safe in everyday clinical practice. **You may be eligible if...** - You are a child aged 6–17 years with moderate to severe active Crohn's disease - You have not previously received infliximab - You or your guardian can provide written consent **You may NOT be eligible if...** - You have a serious infection, active tuberculosis, or cancer (lymphoma or other) - You have moderate-to-severe heart failure - You are allergic to infliximab or similar medications - You are already taking another biologic drug targeting the same pathway (anti-TNF) - You have received a live vaccine within the past 3 months or plan to during treatment - You are enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.